Castle Biosciences Inc (CSTL)vsMerck & Company Inc (MRK)
CSTL
Castle Biosciences Inc
$19.83
+3.07%
HEALTHCARE · Cap: $583.55M
MRK
Merck & Company Inc
$111.38
-0.82%
HEALTHCARE · Cap: $277.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 19006% more annual revenue ($65.77B vs $344.23M). MRK leads profitability with a 13.6% profit margin vs -7.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
CSTL
Avoid33
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.9%
Fair Value
$94.72
Current Price
$19.83
$74.89 discount
Margin of Safety
-13.8%
Fair Value
$97.84
Current Price
$111.38
$13.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.8% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.2% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CSTL
The strongest argument for CSTL centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CSTL
The primary concerns for CSTL are Revenue Growth, Market Cap, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CSTL profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
CSTL carries more volatility with a beta of 1.11 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 33/100). CSTL offers better value entry with a 65.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Castle Biosciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Castle Biosciences Inc. is a cutting-edge diagnostics company dedicated to transforming patient care through its innovative gene-expression profiling tests, particularly in the realm of skin cancer. Its flagship product, DecisionDx®-Melanoma, is instrumental in the management of melanoma, providing critical insights into patient risk stratification and treatment decision-making. With a robust commitment to precision medicine, Castle is actively expanding its portfolio of assays to address unmet clinical needs. Bolstered by a strong research and development focus and an ambitious pipeline, the company is strategically positioned for sustainable growth while enhancing clinical outcomes and delivering significant value to its shareholders in the evolving oncology marketplace.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?